Lindbrook Capital’s Mersana Therapeutics MRSN Stock Holding History

Lindbrook Capital’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18	Closed	-$2.61K	–	2877
2022 Q4	$2.61K	Hold	18	–	–	﹤0.01%	2117
2022 Q3	$3K	Buy	+18	New	+$2.92K	﹤0.01%	1893
2022 Q2	–	Sell	-26	Closed	-$2.44K	–	2681
2022 Q1	$3K	Buy	+26	New	+$3.04K	﹤0.01%	1846
2020 Q3	–	Sell	-20	Closed	-$12K	–	1813
2020 Q2	$12K	Buy	+20	New	+$6.83K	﹤0.01%	780
2020 Q1	–	Sell	-80	Closed	-$14K	–	1804
2019 Q4	$11K	Buy	+80	New	+$5.85K	﹤0.01%	905

Other funds holding MRSN

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return